Two Sigma Advisers’s Innate Pharma IPHA Stock Holding History

Two Sigma Advisers’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,300	Closed	-$56K	–	2809
2021 Q4	$56K	Buy	+12,300	New	+$65.4K	﹤0.01%	2464

Other funds holding IPHA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

Two Sigma Advisers's IPHA Position: Q1 2022 in Review

Two Sigma Advisers sold out of Innate Pharma (IPHA) in Q1 2022, closing a stake of 12,300 shares — an estimated $56K sold.

Two Sigma Advisers first reported a position in IPHA in Q4 2021 and held it in 1 quarter. The position peaked at $56K in Q4 2021. 13 funds tracked by Wall St. Rank hold IPHA as of Q1 2022.

Two Sigma Advisers reported no remaining Innate Pharma position as of Q1 2022 after selling out during the quarter.
Two Sigma Advisers sold 12,300 Innate Pharma shares in Q1 2022, an estimated $56K.
Two Sigma Advisers first reported a position in Innate Pharma in Q4 2021 and held it in 1 quarter.
Two Sigma Advisers's Innate Pharma position peaked at $56K in Q4 2021.
13 funds tracked by Wall St. Rank held Innate Pharma as of Q1 2022.

Based on Two Sigma Advisers's 13F filing for Q1 2022, filed 16 May 2022.